Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trial.

Conditions

Acute ischemic stroke

Brief summary

Favorable functional outcome defined by a modified Rankin Scale (mRS) score ≤ 2 at 3 months.

Detailed description

mRS shift analysis at 3 months., a. Rate of near or complete reperfusion at end of treatment defined by modified treatment in cerebral infarction (mTICI) score 2c or 3. b. Rate of successful reperfusion at end of treatment defined by modified treatment in cerebral infarction (mTICI) score of 2b or 2c or 3., Change in NIHSS from baseline to 24 hours after treatment., Volume assessed by the ASPECTS score (Assessment in Acute Stroke Alberta Stroke Program Early CT) at 24-36 hours., Rate of all-cause mortality at 3 months., Rate of symptomatic intracranial hemorrhage according the Heidelberg definition associated to at least 4 points worsening in NIHSS at 24-36h after treatment., Rate of any intracranial hemorrhage according the Heidelberg definition at 24-36h after treatment.

Related papers

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGKengrexal 50 mg powder for concentrate for solution for injection/infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Favorable functional outcome defined by a modified Rankin Scale (mRS) score ≤ 2 at 3 months.	—

Secondary

Measure	Time frame
mRS shift analysis at 3 months., a. Rate of near or complete reperfusion at end of treatment defined by modified treatment in cerebral infarction (mTICI) score 2c or 3. b. Rate of successful reperfusion at end of treatment defined by modified treatment in cerebral infarction (mTICI) score of 2b or 2c or 3., Change in NIHSS from baseline to 24 hours after treatment., Volume assessed by the ASPECTS score (Assessment in Acute Stroke Alberta Stroke Program Early CT) at 24-36 hours., Rate of all-cause mortality at 3 months., Rate of symptomatic intracranial hemorrhage according the Heidelberg definition associated to at least 4 points worsening in NIHSS at 24-36h after treatment., Rate of any intracranial hemorrhage according the Heidelberg definition at 24-36h after treatment.	—

Measure

Time frame

mRS shift analysis at 3 months., a. Rate of near or complete reperfusion at end of treatment defined by modified treatment in cerebral infarction (mTICI) score 2c or 3. b. Rate of successful reperfusion at end of treatment defined by modified treatment in cerebral infarction (mTICI) score of 2b or 2c or 3., Change in NIHSS from baseline to 24 hours after treatment., Volume assessed by the ASPECTS score (Assessment in Acute Stroke Alberta Stroke Program Early CT) at 24-36 hours., Rate of all-cause mortality at 3 months., Rate of symptomatic intracranial hemorrhage according the Heidelberg definition associated to at least 4 points worsening in NIHSS at 24-36h after treatment., Rate of any intracranial hemorrhage according the Heidelberg definition at 24-36h after treatment.

—

Countries

France

Outcome results

None listed